Nestle pays $98M for increased stake in food allergy drugmaker Aimmune

Alia Paavola - Print  | 

Nestle's health science arm will pay $98 million to increase  its stake in Aimmune Therapeutics, which is preparing to submit an FDA filing for its peanut allergy treatment, Reuters reports.

The deal, which brings Nestle's total investment to $273 million, raises Nestle's stake in the drug developer to about 19 percent from 14.5 percent. The two companies also extended their two-year pact to develop therapies for food allergies by two years.

In the U.S. there is no approved treatment for peanut allergies, so drugmakers see a huge opportunity in the market.

Read the full report here.

More articles on pharmacy:
Walgreens managers lose thousands in bonuses: 3 things to know
14 pharma companies post Q3 profits over $1B
Neulasta biosimilar will get $4,175 price tag

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.

To receive the latest hospital and health system business and legal news and analysis from Becker's Hospital Review, sign-up for the free Becker's Hospital Review E-weekly by clicking here.